New pill joins fight against advanced liver cancer in major trial
NCT ID NCT06680258
Summary
This study aims to see if adding a new oral drug, TPST-1120, to the current standard treatment helps adults with advanced liver cancer live longer. About 740 participants will be randomly assigned to take either the new drug combination or the standard treatment alone. The main goal is to compare overall survival, while also checking safety and if the new combo better shrinks tumors or delays cancer growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.